adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
Published 9 years ago • 206 plays • Length 5:29Download video MP4
Download video MP3
Similar videos
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
7:40
adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
4:03
aphinity: adding pertuzumab to trastuzumab plus chemotherapy in patients with operable her2-posi...
-
6:47
extended adjuvant therapy for her2-positive early breast cancer
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
9:13
substituting trastuzumab emtansine for adjuvant trastuzumab improved idfs for breast cancer pati...
-
5:42
updates on managing her2-positive early breast cancer
-
10:05
piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
-
32:54
raising the bar in her2-positive breast cancer
-
52:21
new & supporting data for optimizing therapy in her2 breast cancer | dr. irene and dr. vogel
-
4:20
peri-operative lapatinib has profound antiproliferative effect in early breast cancer
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
3:50
update from kaitlin for high-risk her2-positive early breast cancer
-
5:00
adjuvant endocrine therapy used to treat er her2- breast cancer
-
5:11
finding appropriate doses for her2 positive breast cancers
-
51:56
new & supporting data for optimizing therapy in her2 breast cancer | dr. kaklamani and dr. o’regan